### FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number: 3235-02									
ı										
ı	Estimated average burden									
ı	hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934	nours per response.
or Section 30(h) of the Investment Company Act of 1940	
2. Issuer Name <b>and</b> Ticker or Trading Symbol Celladon Corp [ CLDN ]	Relationship of Reporting Person(s) to Issuer (Check all applicable)     No Director 10% Owner
3. Date of Earliest Transaction (Month/Day/Year) 02/09/2015	X Officer (give title Other (specify below) below)  Chief Executive Officer
4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)
	X Form filed by One Reporting Person  Form filed by More than One Reporting  Person
	or Section 30(h) of the Investment Company Act of 1940  2. Issuer Name and Ticker or Trading Symbol  Celladon Corp [ CLDN ]  3. Date of Earliest Transaction (Month/Day/Year)  02/09/2015

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	v			Transaction(s) (Instr. 3 and 4)		(111301.4)		
Common Stock	02/09/2015		M		41,302	A	\$1.12	44,427(1)	D		
Common Stock	02/09/2015		M		6,629	A	\$8	51,056(1)	D		
Common Stock	02/09/2015		S <sup>(2)</sup>		41,302	D	\$15.85 <sup>(3)</sup>	9,754 <sup>(1)</sup>	D		
Common Stock	02/09/2015		<b>S</b> <sup>(2)</sup>		6,629	D	\$15.94(4)	3,125(1)	D		

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

7															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock option (right to buy)	\$1.12	02/09/2015		M			41,302	01/27/2013 <sup>(5)</sup>	06/14/2022	Common Stock	41,302	\$0.00	748,208	D	
Stock option (right to	\$8	02/09/2015		M			6,629	01/29/2015 <sup>(6)</sup>	01/28/2024	Common Stock	6,629	\$0.00	741,579	D	

# **Explanation of Responses:**

- 1. The amount includes shares purchased under Celladon Corporation's employee stock purchase plan prior to the reported transaction.
- 2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person.
- 3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$15.69 to \$16.31 per share, inclusive. The reporting person undertakes to provide to Celladon Corporation, any security holder of Celladon Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$15.70 to \$16.26 per share, inclusive. The reporting person undertakes to provide to Celladon Corporation, any security holder of Celladon Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 5. 25% of the shares subject to the option vested and became exercisable on the one year anniversary of January 27, 2012 (the "Vesting Commencement Date"), and 1/48th of the shares vest in equal monthly installments thereafter, over the remaining three years.
- 6. 25% of the shares subject to the option vested and became exercisable on the one year anniversary of January 29, 2014 (the "Vesting Commencement Date"), and 1/48th of the shares vest in equal monthly installments thereafter, over the remaining three years

### Remarks:

/s/ Rebecque J. Laba, Attorney-02/09/2015 in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.